A share price of Zentalis Pharmaceuticals Inc [ZNTL] is currently trading at $3.32, up 21.61%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZNTL shares have gain 17.31% over the last week, with a monthly amount glided 3.75%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to a Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $2.66 and $18.24. Currently, Wall Street analysts expect the stock to reach $21.86 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $3.32 at the most recent close of the market. An investor can expect a potential return of 558.43% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.17%, Pretax Profit Margin comes in at -4.56%, and Net Profit Margin reading is -4.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.44 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.91 points at the first support level, and at 2.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.54, and for the 2nd resistance point, it is at 3.75.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] is 6.59. In addition, the Quick Ratio stands at 6.59 and the Cash Ratio stands at 0.55. Considering the valuation of this stock, the price to sales ratio is 7.08, the price to book ratio is 0.62.
Transactions by insiders
Recent insider trading involved Diana Hausman, Former Chief Medical Officer, that happened on Oct 31 ’24 when 9888.0 shares were purchased. Principal Accounting Officer, Vultaggio Vincent completed a deal on Oct 04 ’24 to sell 1603.0 shares. Meanwhile, President, Interim CFO Gallagher Cam sold 9597.0 shares on May 31 ’24.
